26 January 2019 - CVS Health has added new migraine drugs from Teva Pharmaceutical Industries and Eli Lilly to its list of covered drugs, excluding a rival treatment from Amgen.

CVS’s decision represents a setback for sales of Amgen’s Aimovig, as many patients who rely on the coverage list will now have easier access to the rival Teva and Lilly drugs. Inclusion on the preferred drugs lists by the largest pharmacy benefit managers and health insurers is seen as critically important for sales of new medicines.

An Amgen spokeswoman said the company was disappointed by the CVS decision and that it would work toward Aimovig being a preferred brand on CVS coverage lists.

Read Reuters article